Pioneering cellular medicines for women’s health
We’re developing off-the-shelf cell therapies for high-impact women’s diseases, with lead programs in ovarian cancer, triple negative breast cancer and endometriosis.
Pioneering excellence in the field of immunotherapy
Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers, endometriosis and Alzheimer’s disease. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer and beyond.
Some of our partners
Latest news
Cartherics Wins ‘Most Promising iPSC Therapy Pipeline in APAC’ at Asia Pacific Cell & Gene Therapy Excellence Awards
By Christine Filippis / September 11, 2025
Melbourne, Australia, 11 September 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies...
Read More
Cartherics CEO Prof. Alan Trounson featured on 10News+
By Christine Filippis / September 2, 2025
Cartherics is proud to share that our CEO, Professor Alan Trounson, was recently interviewed on 10 News+ by journalists Amelia...
Read More
Cartherics Granted Chinese Patent for Enhancing Immune Cell Function
By Christine Filippis / August 27, 2025
Melbourne, Australia, 27 August 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies...
Read More
